ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2025

Feb 11, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2025-02-07

Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-07	Common Stock	A	9550	$20.10	Acquired	3773802	Direct

Footnotes

F1: Shares represent equity in lieu of part of his year-end cash bonus.

F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.